Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTILXZYL)

DOT Name Baculoviral IAP repeat-containing protein 5 (BIRC5)
Synonyms Apoptosis inhibitor 4; Apoptosis inhibitor survivin
Gene Name BIRC5
UniProt ID
BIRC5_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1E31; 1F3H; 1XOX; 2QFA; 2RAW; 2RAX; 3UEC; 3UED; 3UEE; 3UEF; 3UEG; 3UEH; 3UEI; 3UIG; 3UIH; 3UII; 3UIJ; 3UIK; 4A0I; 4A0J; 4A0N; 6SHO; 6YIE; 6YIF; 6YIH; 7LBK; 7LBO; 7LBP; 7LBQ
Pfam ID
PF00653
Sequence
MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFC
FKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNK
KKEFEETAKKVRRAIEQLAAMD
Function
Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localization of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. The acetylated form represses STAT3 transactivation of target gene promoters. May play a role in neoplasia. Inhibitor of CASP3 and CASP7. Essential for the maintenance of mitochondrial integrity and function. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform.
Tissue Specificity
Expressed only in fetal kidney and liver, and to lesser extent, lung and brain . Abundantly expressed in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in high-grade lymphomas . Also expressed in various renal cell carcinoma cell lines . Expressed in cochlea including the organ of Corti, the lateral wall, the interdental cells of the Limbus as well as in Schwann cells and cells of the cochlear nerve and the spiral ganglions (at protein level). Not expressed in cells of the inner and outer sulcus or the Reissner's membrane (at protein level) .
KEGG Pathway
Platinum drug resistance (hsa01524 )
Apoptosis (hsa04210 )
Apoptosis - multiple species (hsa04215 )
Hippo sig.ling pathway (hsa04390 )
Hepatitis B (hsa05161 )
Pathways in cancer (hsa05200 )
Chemical carcinogenesis - receptor activation (hsa05207 )
Colorectal cancer (hsa05210 )
Reactome Pathway
Separation of Sister Chromatids (R-HSA-2467813 )
Resolution of Sister Chromatid Cohesion (R-HSA-2500257 )
SUMOylation of DNA replication proteins (R-HSA-4615885 )
RHO GTPases Activate Formins (R-HSA-5663220 )
Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807 )
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain (R-HSA-6803205 )
Mitotic Prometaphase (R-HSA-68877 )
Neddylation (R-HSA-8951664 )
EML4 and NUDC in mitotic spindle formation (R-HSA-9648025 )
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal (R-HSA-141444 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 7 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Selenium DM25CGV Approved Baculoviral IAP repeat-containing protein 5 (BIRC5) affects the response to substance of Selenium. [91]
Melphalan DMOLNHF Approved Baculoviral IAP repeat-containing protein 5 (BIRC5) affects the response to substance of Melphalan. [92]
Imatinib DM7RJXL Approved Baculoviral IAP repeat-containing protein 5 (BIRC5) decreases the response to substance of Imatinib. [93]
Docetaxel DMDI269 Approved Baculoviral IAP repeat-containing protein 5 (BIRC5) decreases the response to substance of Docetaxel. [94]
Epirubicin DMPDW6T Approved Baculoviral IAP repeat-containing protein 5 (BIRC5) decreases the response to substance of Epirubicin. [96]
IB-MECA DM9G5XD Phase 3 Baculoviral IAP repeat-containing protein 5 (BIRC5) decreases the response to substance of IB-MECA. [97]
UCN-01 DMUNJZB Phase 2 Baculoviral IAP repeat-containing protein 5 (BIRC5) decreases the response to substance of UCN-01. [98]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)
This DOT Affected the Regulation of Drug Effects of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Adenosine triphosphate DM79F6G Approved Baculoviral IAP repeat-containing protein 5 (BIRC5) increases the abundance of Adenosine triphosphate. [95]
------------------------------------------------------------------------------------
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of Baculoviral IAP repeat-containing protein 5 (BIRC5). [1]
------------------------------------------------------------------------------------
97 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [2]
Tretinoin DM49DUI Approved Tretinoin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [3]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [4]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [5]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [6]
Cisplatin DMRHGI9 Approved Cisplatin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [5]
Estradiol DMUNTE3 Approved Estradiol decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [7]
Quercetin DM3NC4M Approved Quercetin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [8]
Temozolomide DMKECZD Approved Temozolomide increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [9]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [10]
Hydrogen peroxide DM1NG5W Approved Hydrogen peroxide decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [11]
Calcitriol DM8ZVJ7 Approved Calcitriol decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [12]
Vorinostat DMWMPD4 Approved Vorinostat decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [13]
Testosterone DM7HUNW Approved Testosterone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [12]
Triclosan DMZUR4N Approved Triclosan decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [14]
Decitabine DMQL8XJ Approved Decitabine decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [15]
Marinol DM70IK5 Approved Marinol decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [16]
Zoledronate DMIXC7G Approved Zoledronate decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [17]
Progesterone DMUY35B Approved Progesterone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [18]
Menadione DMSJDTY Approved Menadione affects the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [19]
Fluorouracil DMUM7HZ Approved Fluorouracil decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [20]
Panobinostat DM58WKG Approved Panobinostat decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [21]
Fulvestrant DM0YZC6 Approved Fulvestrant decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [22]
Dexamethasone DMMWZET Approved Dexamethasone affects the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [23]
Folic acid DMEMBJC Approved Folic acid increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [24]
Niclosamide DMJAGXQ Approved Niclosamide decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [25]
Isotretinoin DM4QTBN Approved Isotretinoin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [26]
Bortezomib DMNO38U Approved Bortezomib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [27]
Troglitazone DM3VFPD Approved Troglitazone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [28]
Hydroquinone DM6AVR4 Approved Hydroquinone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [29]
Rosiglitazone DMILWZR Approved Rosiglitazone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [30]
Azathioprine DMMZSXQ Approved Azathioprine decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [31]
Aspirin DM672AH Approved Aspirin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [32]
Etoposide DMNH3PG Approved Etoposide increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [7]
Irinotecan DMP6SC2 Approved Irinotecan decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [33]
Paclitaxel DMLB81S Approved Paclitaxel decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [34]
Nicotine DMWX5CO Approved Nicotine increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [35]
Piroxicam DMTK234 Approved Piroxicam increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [36]
Dasatinib DMJV2EK Approved Dasatinib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [37]
Indomethacin DMSC4A7 Approved Indomethacin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [38]
Simvastatin DM30SGU Approved Simvastatin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [39]
Gemcitabine DMSE3I7 Approved Gemcitabine decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [40]
Mitoxantrone DMM39BF Approved Mitoxantrone increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [10]
Sulindac DM2QHZU Approved Sulindac decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [41]
Capsaicin DMGMF6V Approved Capsaicin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [42]
Lucanthone DMZLBUO Approved Lucanthone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [43]
Methamphetamine DMPM4SK Approved Methamphetamine decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [44]
Daunorubicin DMQUSBT Approved Daunorubicin increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [45]
Palbociclib DMD7L94 Approved Palbociclib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [46]
Acetic Acid, Glacial DM4SJ5Y Approved Acetic Acid, Glacial increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [47]
Motexafin gadolinium DMEJKRF Approved Motexafin gadolinium increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [47]
Bicalutamide DMZMSPF Approved Bicalutamide decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [48]
Vitamin C DMXJ7O8 Approved Vitamin C decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [49]
Sorafenib DMS8IFC Approved Sorafenib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [50]
Gefitinib DM15F0X Approved Gefitinib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [51]
Sodium phenylbutyrate DMXLBCQ Approved Sodium phenylbutyrate decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [21]
Ritonavir DMU764S Approved Ritonavir decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [52]
Bexarotene DMOBIKY Approved Bexarotene decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [53]
Nitric Oxide DM1RBYG Approved Nitric Oxide decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [54]
Lovastatin DM9OZWQ Approved Lovastatin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [55]
Etretinate DM2CZFA Approved Etretinate decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [53]
Melatonin DMKWFBT Approved Melatonin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [56]
Tacrolimus DMZ7XNQ Approved Tacrolimus decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [3]
Crizotinib DM4F29C Approved Crizotinib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [57]
Cantharidin DMBP5N3 Approved Cantharidin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [58]
Lapatinib DM3BH1Y Approved Lapatinib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [59]
Chlorambucil DMRKE63 Approved Chlorambucil affects the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [60]
Etodolac DM6WJO9 Approved Etodolac decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [61]
Methoxsalen DME8FZ9 Approved Methoxsalen decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [62]
Digitoxin DMWVIGP Approved Digitoxin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [64]
Olaparib DM8QB1D Approved Olaparib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [65]
Osimertinib DMRJLAT Approved Osimertinib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [66]
Plicamycin DM7C8YV Approved Plicamycin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [67]
Riboflavin DM8YMWE Approved Riboflavin affects the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [68]
Dacarbazine DMNPZL4 Approved Dacarbazine increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [69]
Memantine DMD9WSC Approved Memantine decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [70]
Ciclopirox DMN5T2A Approved Ciclopirox decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [71]
Pirfenidone DM6VZFQ Approved Pirfenidone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [21]
Resveratrol DM3RWXL Phase 3 Resveratrol decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [72]
Curcumin DMQPH29 Phase 3 Curcumin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [73]
Camptothecin DM6CHNJ Phase 3 Camptothecin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [74]
Seocalcitol DMKL9QO Phase 3 Seocalcitol decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [75]
Chlorpromazine DMBGZI3 Phase 3 Trial Chlorpromazine decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [76]
HMPL-004 DM29XGY Phase 3 HMPL-004 decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [77]
Napabucasin DMDZ6Q3 Phase 3 Napabucasin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [78]
I3C DMIGFOR Phase 3 I3C decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [79]
Crocin DM5F24X Phase 3 Crocin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [80]
Buparlisib DM1WEHC Phase 3 Buparlisib decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [81]
Rebamipide DM2GHCR Phase 3 Rebamipide decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [82]
ABT-263 DMNE56X Phase 3 ABT-263 decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [83]
Genistein DM0JETC Phase 2/3 Genistein decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [84]
Thymoquinone DMVDTR2 Phase 2/3 Thymoquinone decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [85]
Belinostat DM6OC53 Phase 2 Belinostat decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [86]
phorbol 12-myristate 13-acetate DMJWD62 Phase 2 phorbol 12-myristate 13-acetate increases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [87]
BAICALEIN DM4C7E6 Phase 2 BAICALEIN decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [88]
Puerarin DMJIMXH Phase 2 Puerarin decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [89]
Flavopiridol DMKSUOI Phase 2 Flavopiridol decreases the expression of Baculoviral IAP repeat-containing protein 5 (BIRC5). [90]
------------------------------------------------------------------------------------
⏷ Show the Full List of 97 Drug(s)
2 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT
Drug Name Drug ID Highest Status Interaction REF
Reserpine DM6VM38 Approved Reserpine affects the binding of Baculoviral IAP repeat-containing protein 5 (BIRC5). [63]
Berberine DMC5Q8X Phase 4 Berberine affects the binding of Baculoviral IAP repeat-containing protein 5 (BIRC5). [63]
------------------------------------------------------------------------------------

References

1 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
2 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
3 CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
4 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
5 Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett. 2002 Jun 6;180(1):91-101. doi: 10.1016/s0304-3835(01)00834-5.
6 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
7 Estrogen regulation of apoptosis in osteoblasts. Physiol Behav. 2010 Feb 9;99(2):181-5. doi: 10.1016/j.physbeh.2009.04.025. Epub 2009 May 5.
8 Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
9 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
10 [Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):347-50.
11 Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
12 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
13 Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005 Sep 1;11(17):6382-9. doi: 10.1158/1078-0432.CCR-05-0344.
14 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
15 DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
16 Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
17 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
18 Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
19 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
20 Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006 May 18;5:20. doi: 10.1186/1476-4598-5-20.
21 Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS One. 2018 Nov 27;13(11):e0207915. doi: 10.1371/journal.pone.0207915. eCollection 2018.
22 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
23 Dexamethasone affects Fas- and serum deprivation-induced cell death of human osteoblastic cells through survivin regulation. Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1153-65. doi: 10.1177/039463201002300419.
24 Higher Concentrations of Folic Acid Cause Oxidative Stress, Acute Cytotoxicity, and Long-Term Fibrogenic Changes in Kidney Epithelial Cells. Chem Res Toxicol. 2022 Nov 21;35(11):2168-2179. doi: 10.1021/acs.chemrestox.2c00258. Epub 2022 Nov 10.
25 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
26 Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett. 2005 Nov 18;229(2):271-81. doi: 10.1016/j.canlet.2005.06.047. Epub 2005 Aug 30.
27 The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4706-19. doi: 10.1167/iovs.06-1147.
28 Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
29 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
30 All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur J Haematol. 2009 Sep;83(3):191-202. doi: 10.1111/j.1600-0609.2009.01277.x. Epub 2009 May 8.
31 A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
32 Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol. 2007 Dec;72(6):1586-92. doi: 10.1124/mol.107.039610. Epub 2007 Sep 11.
33 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
34 Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther. 2005 Jul;4(7):716-9. doi: 10.4161/cbt.4.7.1782. Epub 2005 Jul 2.
35 Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6332-7. doi: 10.1073/pnas.0509313103. Epub 2006 Apr 6.
36 Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
37 Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
38 [Indomethacin induces apoptosis through inhibition of survivin regulated by beta-catenin/TCF4 in human colorectal cancer cells]. Ai Zheng. 2004 Jul;23(7):737-41.
39 Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
40 Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting -catenin signaling pathway. Chem Biol Interact. 2024 Jan 5;387:110816. doi: 10.1016/j.cbi.2023.110816. Epub 2023 Nov 22.
41 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
42 Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res. 2007 May 15;13(10):3024-32. doi: 10.1158/1078-0432.CCR-06-2575.
43 Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.
44 Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
45 Identification of the key pathway of oxazolinoanthracyclines mechanism of action in cells derived from human solid tumors. Toxicol Appl Pharmacol. 2016 Dec 15;313:159-169. doi: 10.1016/j.taap.2016.10.018. Epub 2016 Oct 22.
46 Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
47 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
48 Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
49 Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer. 2011;63(7):1133-42. doi: 10.1080/01635581.2011.605984. Epub 2011 Sep 15.
50 Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
51 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
52 Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood. 2006 Jan 15;107(2):716-24. doi: 10.1182/blood-2005-02-0735. Epub 2005 Sep 20.
53 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
54 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
55 Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem. 2007 Jul 6;282(27):19273-81. doi: 10.1074/jbc.M610350200. Epub 2007 May 1.
56 Melatonin increases the anticancer potential of doxorubicin in Caco-2 colorectal cancer cells. Environ Toxicol. 2021 Jun;36(6):1061-1069. doi: 10.1002/tox.23105. Epub 2021 Jan 28.
57 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
58 [Apoptosis induced by cantharidin in human pulmonary carcinoma cells A549 and its molecular mechanisms]. Zhonghua Zhong Liu Za Zhi. 2005 Jun;27(6):330-4.
59 Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
60 Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. J Cell Physiol. 2007 Oct;213(1):229-36. doi: 10.1002/jcp.21116.
61 Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol. 2005 Sep 1;70(5):658-67.
62 Down regulation of differentiated embryonic chondrocytes 1 (DEC1) is involved in 8-methoxypsoralen-induced apoptosis in HepG2 cells. Toxicology. 2012 Nov 15;301(1-3):58-65. doi: 10.1016/j.tox.2012.06.022. Epub 2012 Jul 11.
63 Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry. J Mass Spectrom. 2008 Mar;43(3):327-35. doi: 10.1002/jms.1320.
64 Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells. Toxicol Appl Pharmacol. 2012 Jan 1;258(1):51-60. doi: 10.1016/j.taap.2011.10.007. Epub 2011 Oct 18.
65 PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One. 2014 Dec 22;9(12):e114583. doi: 10.1371/journal.pone.0114583. eCollection 2014.
66 Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
67 Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007 Jan 26;282(4):2615-25. doi: 10.1074/jbc.M606203200. Epub 2006 Nov 22.
68 Riboflavin depletion impairs cell proliferation in adult human duodenum: identification of potential effectors. Dig Dis Sci. 2011 Apr;56(4):1007-19. doi: 10.1007/s10620-010-1374-3. Epub 2010 Sep 17.
69 Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004 Dec;14(6):543-6. doi: 10.1097/00008390-200412000-00017.
70 Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells. Hum Exp Toxicol. 2018 Sep;37(9):953-958. doi: 10.1177/0960327117747025. Epub 2017 Dec 11.
71 Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood. 2009 Oct 1;114(14):3064-73. doi: 10.1182/blood-2009-03-209965. Epub 2009 Jul 9.
72 Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell lung carcinoma cells. Biol Chem. 2007 Feb;388(2):207-19.
73 The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis. Int J Mol Med. 2007 Sep;20(3):329-35.
74 SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes. Toxicol Appl Pharmacol. 2014 Jun 15;277(3):288-97. doi: 10.1016/j.taap.2014.04.001. Epub 2014 Apr 12.
75 Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer. 2008 Sep 15;123(6):1376-84. doi: 10.1002/ijc.23667.
76 Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
77 Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicol Lett. 2013 Sep 12;222(1):23-35. doi: 10.1016/j.toxlet.2013.06.241. Epub 2013 Jul 8.
78 Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016 Jun;5(6):1251-8. doi: 10.1002/cam4.675. Epub 2016 Feb 21.
79 Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005 Sep;4(9):1201-15. doi: 10.4161/cc.4.9.1993. Epub 2005 Sep 6.
80 Crocin treatment promotes the oxidative stress and apoptosis in human thyroid cancer cells FTC-133 through the inhibition of STAT/JAK signaling pathway. J Biochem Mol Toxicol. 2021 Jan;35(1):e22608. doi: 10.1002/jbt.22608. Epub 2020 Sep 4.
81 Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol. 2019 Nov;116:105615. doi: 10.1016/j.biocel.2019.105615. Epub 2019 Sep 17.
82 Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun. 2005 Aug 19;334(1):207-12. doi: 10.1016/j.bbrc.2005.05.204.
83 Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. Toxicol In Vitro. 2018 Feb;46:229-236. doi: 10.1016/j.tiv.2017.09.023. Epub 2017 Sep 23.
84 Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells. Mol Carcinog. 2006 Oct;45(10):752-63.
85 Thymoquinone induces apoptosis of human epidermoid carcinoma A431?cells through ROS-mediated suppression of STAT3. Chem Biol Interact. 2019 Oct 1;312:108799. doi: 10.1016/j.cbi.2019.108799. Epub 2019 Aug 18.
86 Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs. 2009 Sep;20(8):682-92.
87 Comparison of gene expression profiles in HepG2 cells exposed to arsenic, cadmium, nickel, and three model carcinogens for investigating the mechanisms of metal carcinogenesis. Environ Mol Mutagen. 2009 Jan;50(1):46-59.
88 Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther. 2007 Nov;6(11):3039-48. doi: 10.1158/1535-7163.MCT-07-0281.
89 [Apoptosis of NB4 cells induced by flavonoids of puerarin in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Apr;18(2):326-9.
90 Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003 Jan 1;63(1):93-9.
91 Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther. 2007 Sep;6(9):2572-80. doi: 10.1158/1535-7163.MCT-07-0172.
92 Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications. Mol Cancer Ther. 2005 Dec;4(12):2016-25. doi: 10.1158/1535-7163.MCT-05-0138.
93 Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res. 2005 Sep 15;65(18):8224-32. doi: 10.1158/0008-5472.CAN-05-0303.
94 [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
95 The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. Toxicol Appl Pharmacol. 2020 Aug 15;401:115080. doi: 10.1016/j.taap.2020.115080. Epub 2020 Jun 1.
96 [Antisense oligonucleotide targeting survivin induces apoptosis of renal clear-cell carcinoma cells and enhances their sensitivity to epirubicin in vitro]. Zhonghua Zhong Liu Za Zhi. 2005 Aug;27(8):468-70.
97 Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possible relationship to the effects on inhibitor of apoptosis protein levels. Chemotherapy. 2005 Aug;51(5):272-9. doi: 10.1159/000087255. Epub 2005 Jul 26.
98 A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines. Invest New Drugs. 2005 Aug;23(4):299-309. doi: 10.1007/s10637-005-1438-y.